Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate reported Q3 2021 results with revenues of $442.1 million, a 55% increase year-over-year. Adjusted revenues reached $442.2 million, up 54%. Net income improved to $0.9 million from a loss of $182 million in Q3 2020. Adjusted EBITDA rose 76% to $190 million. Notably, organic revenues increased 3%. The company maintains a strong outlook for Q4, projecting organic growth of 6%-8%. Additionally, a $250 million share repurchase program extension was approved, enhancing shareholder value.
Clarivate Plc (NYSE:CLVT) launched its Annual G20 Scorecard – Research Performance 2021 report, analyzing the research responses of G20 nations to COVID-19. The report reveals that nations with diverse research portfolios, like the US and Germany, are better equipped to address a wide array of COVID-19 challenges. Although Brazil shows strength in biosciences, others, like Mexico, experience declining research investment. The report highlights changes in research output and collaboration across nations, providing insights essential for policymakers and analysts ahead of the G20 Summit.
On October 18, 2021, Clarivate Plc (NYSE: CLVT) appointed Tiffani Shaw as Chief of Staff, effective November 1. In this new role, Shaw will manage administrative activities in the CEO's office and be part of the Executive Leadership Team. Previously, she was Executive VP and COO at the University of Iowa Center for Advancement, managing over $2 billion in assets. Shaw's experience includes roles as CFO and Controller, alongside a strong background in governance and strategic planning.
Clarivate Plc (NYSE: CLVT) celebrates the recognition of five new Nobel Laureates identified as Citation Laureates. This includes awards in Physiology or Medicine, Physics, Chemistry, and Economics, highlighting Clarivate's predictive accuracy since 2002. Notably, 64 Citation Laureates have received this honor, emphasizing the company's unique methodology combining quantitative data and expert analysis. The awards reflect significant contributions by researchers such as David Julius and Giorgio Parisi, showcasing Clarivate's role in advancing scientific recognition.
Clarivate Plc (NYSE: CLVT) announced it will release its third-quarter 2021 financial results on October 28, 2021, before the market opens. The press release and earnings information will be available on the company’s investor website. A conference call and webcast will follow at 8:00 AM Eastern Time the same day, providing insights into the financial results. Interested participants can join the call via phone or through the live webcast. An audio replay will be accessible after the call until November 11, 2021.
Clarivate Plc (NYSE:CLVT) released a Global Research Report analyzing the research landscape of 34 countries in South & Central America, Mexico, and the Caribbean since 1981. The report highlights a rapid growth in academic research output, particularly from South America, with over 25,000 papers published by five leading countries from 2016 to 2020. However, regional collaboration remains low, at about 10%. The report suggests establishing a regional research organization to enhance research capacity and collaboration, echoing successful European models. Key strengths include life sciences, environmental studies, and increasing international collaboration.
Clarivate Plc (NYSE: CLVT) has announced the 2021 Citation Laureates, recognizing 16 elite researchers for their exceptional contributions to science. This year's honorees come from the United States, Japan, France, Italy, Korea, and Singapore, selected based on citation analysis by the Institute for Scientific Information. Only 0.01% of articles indexed in the Web of Science have been cited over 2,000 times, highlighting the significance of these laureates' work. Historical data shows that 59 Citation Laureates have previously received a Nobel Prize.
On September 15, 2021, Clarivate Plc (NYSE: CLVT) announced the release of the 2021 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook. The report reveals a 10-year high for new molecular entities (NMEs), with 59 NMEs launched in 2020, indicating resilience amidst the COVID-19 pandemic. The Factbook offers insights on R&D expenditures, cycle times, and pipeline growth, helping pharma companies benchmark their efforts. Notably, CDC approval times remained stable, reflecting a consistent drug development landscape despite pandemic challenges.
Clarivate Plc (NYSE: CLVT) has announced the pricing of an underwritten public offering of 25,000,000 ordinary shares by affiliated funds of Onex Corporation and Baring Private Equity Asia. The offering is set to close on September 14, 2021, pending customary conditions. An additional 3,750,000 shares may be purchased at the underwriters' discretion. Clarivate will not sell any shares, with proceeds solely benefiting the Selling Shareholders. Citigroup and Barclays are acting as joint book-running managers for this offering.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
